CSCI: COSCIENS Biopharma Company Sales Revenue

Corporate emblem and logo of COSCIENS Biopharma (CSCI)

COSCIENS Biopharma Inc. is currently undergoing a cost optimization phase and a research portfolio review, which is fueling cautious optimism among investors. This revenue chart for the company on GURU.Markets reflects this trend, where the 0.01 mark records this metric. Stability is underpinned by exclusive drug distribution rights in Canada and LATAM, as well as the ownership of the Macrilen patent for diagnosing endocrine pathologies.

CSCI (COSCIENS Bio) Revenue and Sales Volume history from 08/10/2024 to 09/14/2025

Analytical breakdowns for COSCIENS Biopharma Inc.

- current price and projected stock value:
Share Price COSCIENS Bio|CSCI - Consensus Target
- market capitalization information:
Market Value COSCIENS Biopharma Inc.|CSCI - Total Company Value
- balance sheet net asset value indicators:
Share Book Value COSCIENS Biopharma|CSCI - Book Capitalization|Market Value to Book Value cosciensbio.com|CSCI - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital COSCIENS Biopharma Inc|CSCI - Company Debts|Debt to Book Value COSCIENS Biopharma Inc.|CSCI - Company Long-Term Debts|Company Short-Term Debts COSCIENS Biopharma|Quick Liquidity Indicator cosciensbio.com
- net income and valuation multiples indicators:
CSCI - Company Net Income|Expected Net Profit COSCIENS Biopharma Inc.|CSCI - Price to Earnings Ratio|Market Cap to Projected Earnings cosciensbio.com|CSCI - PEG Multiple|Enterprise Value to EBITDA Ratio COSCIENS Biopharma Inc.|CSCI - Operating profit EBITDA|Net earnings per share for the last four quarters COSCIENS Biopharma|CSCI - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months cosciensbio.com|CSCI - Earnings per share growth in current year|Projected earnings per share growth rate for next year COSCIENS Biopharma Inc.
- company sales and revenue statistics:
CSCI - Company Revenue|Company Future Sales COSCIENS Bio|CSCI - Market Cap to Revenue|Forward Price to Sales COSCIENS Biopharma Inc.
Comprehensive company analysis:CSCI COSCIENS Bio
Core merchandise of COSCIENS Biopharma Inc

The monetization of unique patents in the orphan endocrinology segment allows COSCIENS Biopharma Inc. (CSCI) to maintain high margins due to inelastic demand. The trend in the company's aggregate sales figures reflects daily cash inflows, verifying the business's operational resilience and eliminating the risk of reporting manipulation, which makes this chart a key tool for assessing the issuer's financial security.

Key competitors

Company Sales Volume VRTX (Vertex Corp)|Company Sales ALNY (Alnylam Pharmaceuticals)|INSM (insmed.com) - Company Sales Revenue|Company Revenue United Therapeutics Corporation UTHR|BMRN (BioMarin Pharmaceutical Inc.) - Company Annual Revenue|BridgeBio Pharma Inc - Revenue and Sales Volume|Company Sales Revenue BGM (BGM Group Ltd)|COGT: Revenue and Sales Volume|xerispharma.com (XERS) - Revenue and Sales Volume|Company Revenue Keros Therapeutics, Inc.|ARCT: Company Sales Revenue|Company Revenue Eton Pharma (ETON)|Company Sales Kamada Pharma KMDA|Revenue and Sales Volume FULC (Fulcrum Therapeutics)|Revenue and Sales Volume Abeona Therapeutics, Inc. ABEO|Mereo BioPharma Group PLC - Revenue and Sales Volume|Protalix BioTherapeutics Inc. (PLX) - Company Sales|pliantrx.com (PLRX) - Company Revenue|Company Total Revenue Applied Therapeutics Inc. (APLT)|Company Revenue Rein Therapeutics Inc|Gelteq Limited Inc (GELS) - Company Gross Revenue|Revenue and Sales Volume AYTU|Company Sales chemomab.com CMMB|Revenue and Sales Volume SRXH (SRx Health Solutions)|Company Gross Revenue Polyrizon Limited (PLRZ)|Zentaris - Revenue and Sales Volume|Company Total Revenue cyclotherapeutics.com|inozyme.com (INZY) - Company Revenue|Company Sales Volume RPHM